Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
PF-4800567
Подписчиков: 0, рейтинг: 0
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
ChEBI | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H18ClN5O2 |
Molar mass | 359.81 g·mol−1 |
3D model (JSmol) | |
| |
|
PF-4800567 is a drug developed by Pfizer which acts as a selective inhibitor of the enzyme Casein kinase 1 epsilon (CK1-ε), and has mainly been used in the study of the casein kinase 1 enzymes in the regulation of circadian rhythm, as well as showing potential neuroprotective effects. While this research has shown that circadian rhythm is modulated primarily by the alternate isoform CK1-δ rather than CK1-ε, both PF-4800567 and the related non-selective CK1-δ/ε inhibitor PF-670462 were found in animal studies to enhance responses to certain drugs of abuse such as methamphetamine and fentanyl, which suggests a role for CK1-ε in negative regulation of sensitivity to stimulant and opioid drugs.